Skip to content
DataLookout
Menu

NCT05144997

Lorlatinib Continuation Study

StatusActive, Not Recruiting
PhasePhase 4
SponsorPfizer
Primary completion (estimated)

At risk: Primary completion moved at least 2 years 9 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 24 versions: 23 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 28, 2026 to Oct 25, 2029
    • Site details revised at 3 of 27 sites
  2. Minor Enrollment target: 74 to 76
    • Study sites: 35 to 27
    v22
  3. Minor Enrollment target: 73 to 74v21
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 200 to confirmed 73
    • Study sites revised (35)
    v20
  5. Minor Study sites: 33 to 35v19
Show 17 earlier versionsHide 17 earlier versions
  1. Minor Study sites: 31 to 33v18
  2. Minor Study sites: 30 to 31v17
  3. Minor Study sites: 28 to 30v16
  4. Minor Site details revised at 2 of 28 sitesv15
  5. Minor Study sites: 20 to 28v14
  6. Minor Study sites: 17 to 20
    • Primary and study completion dates: Jun 12, 2027 to Dec 28, 2026
    v13
  7. Minor Study sites: 10 to 17
    • Primary and study completion dates: Dec 28, 2026 to Jun 12, 2027
    v12
  8. Minor Site details revised at 1 of 10 sitesv11
  9. Minor Study sites: 9 to 10v10
  10. Minor Study sites: 8 to 9v9
  11. Minor Study sites: 7 to 8v8
  12. Minor Study sites: 6 to 7v7
  13. Minor Study sites: 4 to 6v6
  14. Minor Study sites: 3 to 4
    • Eligibility criteria shortened, about 19 words
    v5
  15. Minor Site details revised at 1 of 3 sitesv4
  16. Minor Study sites: 1 to 3v3
  17. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Primary and study completion dates: Dec 31, 2026 to Dec 28, 2026
    • Start date changed from estimate of Dec 31, 2021 to Dec 28, 2021
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants with adverse events leading to permanent discontinuation of study intervention
Timeframe: Baseline up to approximately 5 years
Number of serious adverse events reported for all participants
Timeframe: Baseline up to approximately 5 years

Arms and interventions

LorlatinibExperimental

Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously

Drugs: Lorlatinib

Sites

27 sites in 8 countries

China 17, France 2, India 2, Singapore 2, Japan 1, Spain 1, Taiwan 1, United States 1